Ways to save money on pharmaceuticals may be the answer for millions of Americans, especially the elderly who are often prescribed multiple medicines, to make ends meet and still maintain their health.
Coupons, generics, substitution of brands and frank discussions with your physician regarding your ability to pay for your Rx are just a few of the options available.
If the 26th amendment in Mississippi passes it is.
The beginning of personhood?
Because the amendment would define a fertilized egg as a person with full legal rights, it could have an impact on a woman’s ability to get the morning-after pill or birth control pills that destroy fertilized eggs, and it could make in vitro fertilization treatments more difficult because it could become illegal to dispose of unused fertilized eggs. This could lead to a nationwide debate about women’s rights and abortion while setting up a possible challenge to the landmark Roe v. Wade case, which makes abortion legal.
The vote is upcoming in Mississippi to declare a fertilized ovum; human egg, a person.
The implications are vast and the arguments many, but in a state with the highest teenage pregnancy and STD rates it looks like the amendment will pass.
Physicians, scientists, women and hospital staff will face a host challenges to deal with the care of patients if this amendment passes.
There are great arguments on both sides.
Considering all the possibilities a new branch of legal practice may be necessary.
The CLASS Obama health care program is not going forward.
Not enough young, healthy people are signing up to make the program financially viable.
The CLASS program was similar to long-term care plans available in the private sector in which workers sign up and pay a monthly premium. It was voluntary and was to be paid for entirely by the premiums from those who signed up. In return, subscribers would get a daily benefit.
Men who receive a diagnosis of prostate cancer are faced with a frightening array of options.
To live with cancer might seem to be unthinkable, however, in light of the alternatives a slow growing cancer may be easier to live with than the side effects of cancer treatment and in the worse case, death from infection and other surgical complications.
Many men who agree to a PSA test do not understand what it is. Some common misconceptions:
— It shows cancer. In fact, PSA is just a measure of inflammation, and it can be elevated for many reasons besides cancer: normal enlargement of the prostate with age, an infection, even recent sex, a strenuous bike ride or horseback riding.
— It’s been proven to save lives. Only two large, well-done studies have looked at this, the task force says. The American study found annual screening did not lower the chances of dying of prostate cancer. However, cancer fear is so great, and belief in the value of screening so ingrained, that half the men assigned to the group not offered PSA tests got one anyway. That made comparisons to the group given annual screening difficult. For that reason, some doctors don’t believe the study’s conclusion.
The other study, conducted in Europe, found a small benefit for certain age groups screened every two to seven years — not annually. However, one Swedish center had such rosy results that scientists think it may have biased the whole study. If that center is excluded, no benefit from the PSA test is seen.— The task force’s stance goes against past advice. Routine PSA testing has been supported by some advocacy groups and by urologists, the doctors who do the tests and treatments. But it has not been pushed by major scientific groups, the American Cancer Society or the government.
— It finds cancer early so you’re more likely to survive. About 90 percent of prostate cancers found through screening are early-stage. Most will grow so slowly they will never threaten a man’s life, but there’s no good way to tell which ones will. Research suggests that tumors causing symptoms are more likely to warrant treatment than those that are not. Also, finding aggressive prostate tumors early may not affect how lethal they prove to be; the PSA test may just let men learn of them sooner than they otherwise would.
Blue Shield of California won’t cover an approved breast cancer drug for women suffering from breast cancer.
For many, this drug is the only thing keeping them alive.
Blue Shield of California will no longer pay for the use of the drug Avastin to treat breast cancer, a sign that support for the widely debated and expensive treatment may be eroding among health plans.
Blue Shield, with 3.2 million members, is apparently the first large insurance company to end payments since a federal advisory committee unanimously recommended in June that the Food and Drug Administration rescind Avastin’s approval as a treatment for breast cancer, saying the drug did not really help patients.
© 2026 MedClient.com
Theme by Anders Noren — Up ↑